Charles Schwab Investment Management Inc. Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Charles Schwab Investment Management Inc. decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 236,157 shares of the specialty pharmaceutical company's stock after selling 14,189 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.12% of ANI Pharmaceuticals worth $13,055,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its position in shares of ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock worth $33,907,000 after purchasing an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. increased its stake in ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after acquiring an additional 340,854 shares during the period. abrdn plc bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $13,155,000. Bank of Montreal Can acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth $13,043,000. Finally, Barclays PLC increased its position in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after purchasing an additional 135,003 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In related news, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $191,776 over the last three months. 12.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on ANIP. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price for the company. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Finally, StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.

ANI Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ ANIP traded up $0.35 during midday trading on Tuesday, hitting $66.33. 536,707 shares of the stock traded hands, compared to its average volume of 241,863. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.81. The business has a 50 day moving average price of $59.63 and a two-hundred day moving average price of $58.14. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market cap of $1.44 billion, a PE ratio of -120.60 and a beta of 0.63.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.